Taken together, the collective evidence strongly supports the notion that GPER1-mediated the activation of cAMP-PKA–dependent AMPK signaling pathway can effectively impede the progression of NAFLD/NASH. Here, GPER1 is linked to metabolic dysfunction-associated steatotic liver disease.